Cite
HARVARD Citation
Hess, G. et al. (2022). A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial. British journal of haematology. pp. 482-491. [Online].